Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

LadRx Corporation (EM) LADX

LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer. In addition, the company develops albumin companion diagnostic (ACDx) to identify patients with cancer that benefits from treatment with the four LADR lead candidates. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. The company was incorporated in 1985 and is headquartered in Los Angeles, Calif...


EXPM:LADX - Post by User

User Avatar Image
(0)
•••
  • winterskyX
Post by winterskyon Jul 06, 2017 11:06pm
348 Views
Post# 26442997

huge news this is big UMB

huge news this is big UMBThe expansion plan includes two buildings and four phases of construction. The first phase is a building envelope of 130,000 sq ft.  Second phase is the second level completion of equal square footage bringing the total of the first building to 260,000 sq ft. The second building, first floor phase three construction, is 80,000 sq ft. Fourth and final phase construction of the second level completes the 420,000 square foot expansion plans. Once the entire project is completed and licensed it has the potential to produce over 110,000 kg of cannabis per year or over $500 million annually.
<< Previous
Bullboard Posts
Next >>